MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimeritnib is the standard treatment for patients with non-small cell lung cancer harboring the EGFR T790M mutation; however, acquired resistance inevitably develops. Therefore, a next-generation treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Ninomiya, Kiichiro, Ohashi, Kadoaki, Makimoto, Go, Tomida, Shuta, Higo, Hisao, Kayatani, Hiroe, Ninomiya, Takashi, Kubo, Toshio, Ichihara, Eiki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792548/
https://www.ncbi.nlm.nih.gov/pubmed/29386539
http://dx.doi.org/10.1038/s41598-018-20326-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792548/
https://www.ncbi.nlm.nih.gov/pubmed/29386539
http://dx.doi.org/10.1038/s41598-018-20326-z

Ejemplares similares